1. Optimizing Use of Biological Agents in Ulcerative Colitis

2. Introduction

3. Case 1: What to Do When Conventional Treatment Fails?

4. Case 1: What to Do When Conventional Treatment Fails? (cont)

5. Safety of Ibuprofen in Patients With IBD

6. Case 1: What to Do When Conventional Treatment Fails? (cont)

7. Endoscopic Remission as Treatment Target

8. The Mayo Endoscopic Subscore

9. Impact of Mucosal Healing on the Course of Disease

10. Case 1: Next Steps

11. Toronto Guidelines for the Management of Moderate to Severe Active UC

12. Toronto Guidelines for the Management of Moderate to Severe Active UC (cont)

13. Toronto Guidelines for Management of Corticosteroid-Resistant/Dependent UC

14. Considerations for Biologic Treatment

15. Vedolizumab: Onset of Action in UC

16. Vedolizumab Real-World Effectiveness: Meta-Analysis

17. Considerations for Starting Biologic Therapy

18. Treating to Target and Monitoring Response

19. Strategies to Optimize Anti-TNF Therapy

20. Vedolizumab Long-Term Safety Outcomes

21. Long-Term Efficacy Outcomes With Biologics

22. Case 2: What to Do When First Anti-TNF Therapy Fails?

23. Case 2: What to Do When First Anti-TNF Therapy Fails? (cont)

24. Case 2: What to Do When First Anti-TNF Therapy Fails? (cont)

25. Algorithm for Management of Patients With Continued Inflammation Receiving Infliximab

26. Algorithm for Management of Patients With Secondary LOR to Biologic

27. Algorithm for Management of Patients With Secondary LOR to Biologic (cont)

28. Pharmacokinetics of Anti-TNF Agents

29. Using Biologic Monotherapy vs Combination

30. Conclusions

31. Abbreviations

32. Abbreviations (cont)